Biomed Industries presented Phase 2 clinical data for NA-931—also known as Bioglutide™—at the European Association for the Study of Diabetes (EASD) meeting in Vienna. According to the company, the oral quadruple receptor agonist achieved weight loss comparable to leading injectables, while demonstrating a favorable safety profile.
NA-931 is engineered to activate four metabolic hormone receptors (IGF-1, GLP-1, GIP, and glucagon) via oral administration, positioning it as a potential alternative to injectable obesity therapies. The Phase 2 trial was a 13-week, randomized, double-blind, placebo-controlled study enrolling 125 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27 with comorbidity).
At the highest tested dose (150 mg daily), Biomed reports mean body weight reduction of 13.8 %, or 11.9 % versus placebo. Up to 72 % of treated patients achieved at least 12 % weight loss, compared with 1.9 % in the placebo arm. Safety findings were described as mild: most gastrointestinal adverse events were “insignificant or mild,” with nausea and vomiting in 7.3 % and diarrhea in 6.3 % of subjects. No muscle loss was observed, the company claims.
Pharmacokinetic results suggest once-daily dosing without regard to food intake. Biomed plans to advance NA-931 into Phase 3 trials. The company also discussed research linking obesity and Alzheimer’s disease, noting parallel development efforts for NA-831 (targeted at Alzheimer’s) alongside NA-931.
